Switch to
| Predicate | Object |
|---|---|
| rdf:type | |
| lifeskim:mentions | |
| pubmed:issue |
6
|
| pubmed:dateCreated |
1977-3-31
|
| pubmed:abstractText |
The availibility of a non-modified gamma globulin for intravenous use should abolish the intramuscular administration of Cohn standard gamma globulin and replace modified products to the greatest possible extent. The product developed in our institute is purified from Cohn fraction II using HES and aluminum silicate for the elimination of aggregates. The product shows excellent purity, stability, and clinical compatibility.
|
| pubmed:language |
eng
|
| pubmed:journal | |
| pubmed:citationSubset |
IM
|
| pubmed:chemical | |
| pubmed:status |
MEDLINE
|
| pubmed:issn |
0323-4347
|
| pubmed:author | |
| pubmed:issnType |
Print
|
| pubmed:volume |
103
|
| pubmed:owner |
NLM
|
| pubmed:authorsComplete |
Y
|
| pubmed:pagination |
938-45
|
| pubmed:dateRevised |
2005-11-17
|
| pubmed:meshHeading | |
| pubmed:year |
1976
|
| pubmed:articleTitle |
Isolation of Non-modified gamma globulin for intravenous use.
|
| pubmed:publicationType |
Journal Article
|